These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22768899)

  • 1. The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation.
    Schnell O; Alawi H; Battelino T; Ceriello A; Diem P; Felton AM; Grzeszczak W; Harno K; Kempler P; Satman I; Vergès B
    J Diabetes Sci Technol; 2012 May; 6(3):665-73. PubMed ID: 22768899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.
    Ahrén B; Carr MC; Murphy K; Perkins C; Rendell M; Mallory J; Wilson T; Johnson S
    Diabetes Res Clin Pract; 2017 Apr; 126():230-239. PubMed ID: 28284167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation.
    Schnell O; Alawi H; Battelino T; Ceriello A; Diem P; Felton AM; Harno K; Satman I; Vergès B
    J Diabetes Sci Technol; 2014 Jul; 8(4):783-90. PubMed ID: 24876442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy.
    Namba M; Katsuno T; Kusunoki Y; Matsuo T; Miuchi M; Miyagawa J
    Clin Exp Nephrol; 2013 Feb; 17(1):10-5. PubMed ID: 23135865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination pharmacotherapy with incretins: what works best and when?
    Over RK; Ratner RE
    Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S20-7. PubMed ID: 20824236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
    Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
    Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; Serné EH; van Raalte DH
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2125-32. PubMed ID: 27562916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.